Dr Bea Mann, PhD, is vice president and oncology therapeutic expert at ICON. As the head of the Oncology Drug Development Services group, Dr Mann is responsible for overseeing the scientific and medical oncology clinical development strategies globally. She brings to ICON more than 16 years of pharmaceutical industry experience (Medical Affairs) having worked as a medical & scientific advisor in the field of oncology and haematology at Roche and GSK. She has extensive experience across all phases of development from pre-clinical to commercialisation. Dr Mann joined ICON in 2016 and in her current role has an expert understanding of the oncology research environment and a thorough understanding of the rapidly changing guidelines for the development of anticancer drugs from study design to protocol development. She has a PhD in Medicinal Chemistry & Drug Development from Nottingham University, UK and was a major contributor to the identification, development, and commercialisation of two linker molecules as part of her oncology research.
